Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

Endocrine therapy resistance occurs often in estrogen receptor positive (ER+) breast cancer. Here, the authors find that 3D epigenome remodelling at ER-bound enhancer-promoter interactions is a key mechanism underlying endocrine resistance.

Saved in:
Bibliographic Details
Main Authors: Joanna Achinger-Kawecka, Fatima Valdes-Mora, Phuc-Loi Luu, Katherine A. Giles, C. Elizabeth Caldon, Wenjia Qu, Shalima Nair, Sebastian Soto, Warwick J. Locke, Nicole S. Yeo-Teh, Cathryn M. Gould, Qian Du, Grady C. Smith, Irene R. Ramos, Kristine F. Fernandez, Dave S. Hoon, Julia M. W. Gee, Clare Stirzaker, Susan J. Clark
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/fa0958eacf7f42d19237b40a66d1a2d1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items